Comparisons of the effect of different dipeptidyl peptidase-4 inhibitor treatment for 1 year on adjusted mean changes in fasting plasma glucose (FPG) (A) and glycated hemoglobin (HbA1c) (B) in the patients with a low and high hemoglobin glycation index (HGI). Factors included in the analysis of variance statistical model were baseline oral anti-diabetes drugs, age, sex and renal function. VI = vildagliptin (n = 24 in the low HGI and n = 36 in the high HGI groups), LI = linagliptin (n = 33 in the low HGI and n = 31 in the high HGI groups), SA = saxagliptin (n = 45 in low HGI and n = 64 in the high HGI groups), SI = sitagliptin (n = 97 in the low HGI and n = 138 in the high HGI group). Error bars represent 95% confidence interval (CI). p-value for between-group difference. (To convert glucose to millimoles per liter, multiply by 0.0555)</p

Chia-Lin Lee (161345)

Chia-Po Fu (3737605)

I-Te Lee (392553)

Jun-Sing Wang (3737608)

Shih-Yi Lin (239494)

Wayne H-H Sheu (521541)

Yu-Wei Chen (488763)

Yuh-Min Song (3737611)

PLoS ONE

PubMed

INTRODUCTION:A high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4 inhibitors. METHODS:This retrospective cohort study followed 468 patients with type 2 diabetes receiving DPP-4 inhibitor treatment for 1 year. Estimated HbA1c was calculated using a linear regression equation derived from another 2969 randomly extracted patients with type 2 diabetes based on fasting plasma glucose (FPG) level. The subjects were divided into two groups based on HGI (HGI = observed HbA1c - estimated HbA1c). Mixed model repeated measures were used to compare the treatment efficacy after 1 year in patients with a low (HGI<0, n = 199) and high HGI (HGI≧0, n = 269). RESULTS:There were no significant group differences in mean changes of FPG after 1 year (-12.8 and -13.4 mg/dL in the low and high HGI groups, respectively). However, the patients with a high HGI had a significantly greater reduction in HbA1c from baseline compared to those with a low HGI (-1.9 versus -0.3% [-20.8 versus -3.3 mmol/mol]). Improvements in glycemic control were statistically significantly associated with the tested DPP-4 inhibitors in the high HGI group (-2.4, -1.4, -1.2 and -2.2% [-26.2, -15.3, -13.1 and -24.0 mmol/mol] for vildagliptin, linagliptin, saxagliptin and sitagliptin, respectively) but not in the low HGI group. CONCLUSIONS:The HGI index derived from FPG and HbA1c may be able to identify who will have a better response to DPP-4 inhibitors

Yu-Wei Chen

Jun-Sing Wang

Wayne H-H Sheu

Shih-Yi Lin

I-Te Lee

Yuh-Min Song

Chia-Po Fu

Chia-Lin Lee

Directory of Open Access Journals

Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.

FigShare

Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes - Fig 2

Csíkos, Csaba

Repository of the Academy's Library

Egy hazai matematikai felmérés

eredményei nemzetközi

összehasonlításban

<div>IntroductionA high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4 inhibitors.MethodsThis retrospective cohort study followed 468 patients with type 2 diabetes receiving DPP-4 inhibitor treatment for 1 year. Estimated HbA1c was calculated using a linear regression equation derived from another 2969 randomly extracted patients with type 2 diabetes based on fasting plasma glucose (FPG) level. The subjects were divided into two groups based on HGI (HGI = observed HbA1c - estimated HbA1c). Mixed model repeated measures were used to compare the treatment efficacy after 1 year in patients with a low (HGI<0, n = 199) and high HGI (HGI≧0, n = 269).ResultsThere were no significant group differences in mean changes of FPG after 1 year (-12.8 and -13.4 mg/dL in the low and high HGI groups, respectively). However, the patients with a high HGI had a significantly greater reduction in HbA1c from baseline compared to those with a low HGI (-1.9 versus -0.3% [-20.8 versus -3.3 mmol/mol]). Improvements in glycemic control were statistically significantly associated with the tested DPP-4 inhibitors in the high HGI group (-2.4, -1.4, -1.2 and -2.2% [-26.2, -15.3, -13.1 and -24.0 mmol/mol] for vildagliptin, linagliptin, saxagliptin and sitagliptin, respectively) but not in the low HGI group.ConclusionsThe HGI index derived from FPG and HbA1c may be able to identify who will have a better response to DPP-4 inhibitors.</div

Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes

Mean value from baseline to 1 year of dipeptidyl peptidase-4 inhibitor treatment in two groups according to baseline hemoglobin glycation index (HGI) in fasting plasma glucose (FPG) (p = 0.965) (A) and glycated hemoglobin (HbA1c) (p < 0.001) (B). Data are presented as mean ± standard deviation (SD). * p = 0.002, **p<0.001 compared with baseline; where ‘p’ represents p-value of between-group difference. (To convert glucose to millimoles per liter, multiply by 0.0555.)</p

Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes - Fig 1

https://figshare.com/articles/Hemoglobin_glycation_index_as_a_useful_predictor_of_therapeutic_responses_to_dipeptidyl_peptidase-4_inhibitors_in_patients_with_type_2_diabetes_-_Fig_1/4637224

Egy hazai matematikai felmérés eredményei nemzetközi összehasonlításban

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals

FigShare

Repository of the Academy's Library

FigShare

FigShare